Inventor
HENDERSON JAMES A
US40 patents
⚠️ This page may combine multiple inventors who share the name “HENDERSON JAMES A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
C4 THERAPEUTICS INC
17 patentsUS11185592B2Nov 30, 2021
Spirocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC20 citations93
US10905768B1Feb 2, 2021
Heterocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC31 citations93
US10660968B2May 26, 2020
Spirocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC32 citations93
US10646575B2May 12, 2020
Heterocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC32 citations93
US10849982B2Dec 1, 2020
C3-carbon linked glutarimide degronimers for target protein degradation
C4 THERAPEUTICS INC43 citations92
US11524949B2Dec 13, 2022
Degraders and Degrons for targeted protein degradation
C4 THERAPEUTICS INC7 citations85
US11459335B2Oct 4, 2022
N/O-linked Degrons and Degronimers for protein degradation
C4 THERAPEUTICS INC8 citations85
US11407732B1Aug 9, 2022
Tricyclic degraders of Ikaros and Aiolos
C4 THERAPEUTICS INC10 citations85
US12048747B2Jul 30, 2024
Substituted piperidine Degronimers for Target Protein degradation
C4 THERAPEUTICS INC4 citations74
US11992531B2May 28, 2024
C3-carbon linked glutarimide degronimers for target protein degradation
C4 THERAPEUTICS INC3 citations73
US12570626B2Mar 10, 2026
Degraders and degrons for targeted protein degradation
C4 THERAPEUTICS INC0 citations62
US12441740B2Oct 14, 2025
N/O-linked degrons and degronimers for protein degradation
C4 THERAPEUTICS INC0 citations62
US12180225B2Dec 31, 2024
N/O-linked degrons and degronimers for protein degradation
C4 THERAPEUTICS INC1 citations62
US12076405B2Sep 3, 2024
Heterocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC1 citations62
US12048748B2Jul 30, 2024
Spirocyclic degronimers for target protein degradation
C4 THERAPEUTICS INC1 citations62
US11753397B2Sep 12, 2023
Cereblon binders for the degradation of ikaros
C4 THERAPEUTICS INC1 citations62
US12454521B2Oct 28, 2025
Targeted protein degradation
C4 THERAPEUTICS INC0 citations48
VERTEX PHARMA
7 patentsUS9676759B2Jun 13, 2017
Isoindolinone inhibitors of phosphatidylinositol 3-kinase
VERTEX PHARMA8 citations83
US8354419B2Jan 15, 2013
Benzimidazole analogues for the treatment or prevention of flavivirus infections
VERTEX PHARMA10 citations82
US10183933B2Jan 22, 2019
Isoindolinone inhibitors of phosphatidylinositol 3-kinase
VERTEX PHARMA1 citations72
US8779156B2Jul 15, 2014
Analogues for the treatment or prevention of flavivirus infections
VERTEX PHARMA7 citations70
US10118904B2Nov 6, 2018
Triazoles for the treatment of Demyelinating Diseases
VERTEX PHARMA3 citations68
US8765731B2Jul 1, 2014
Benzimidazole analogues for the treatment or prevention of flavivirus infections
VERTEX PHARMA1 citations50
US10766869B2Sep 8, 2020
Triazoles for the treatment of demyelinating dieases
VERTEX PHARMA0 citations48
WESTINGHOUSE ELECTRIC CORP
5 patentsUS4124272ANov 7, 1978
Rotary fiber optic waveguide coupling
WESTINGHOUSE ELECTRIC CORP57 citations91
US4653159AMar 31, 1987
Flexible automated manufacturing system
WESTINGHOUSE ELECTRIC CORP65 citations90
US4456329AJun 26, 1984
Optical device having multiple wavelength dependent optical paths
WESTINGHOUSE ELECTRIC CORP31 citations86
US4262362AApr 14, 1981
Fiber optics duplex module
WESTINGHOUSE ELECTRIC CORP21 citations76
US4683636AAug 4, 1987
Wire preparation system
WESTINGHOUSE ELECTRIC CORP10 citations67